EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tumor Marker Test in Cerebrospinal Fluid for Leptomeningeal Metastasis Diagnosis and Response Assessment in Non‐Small‐Cell Lung Cancer

Kaiyuan Huang, Haifeng He, Weili Jin, Xueling Liu, Yuxiang Weng, Danfang Yan, Yilei Zhao, Hanjin Yang, Renya Zhan iD, Qingsheng Xu, Qun Chen iD

European Journal of Neurology · 2025-06 · 32 (6)

DOI: 10.1111/ene.70245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 10.06.2025. Verfasst von Kaiyuan Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor, Meningeal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds Current methods for diagnosis and disease monitoring for leptomeningeal metastasis (LM) face significant challenges, as they are relatively complex and lack the precision needed to detect subtle changes.

Methods

We conducted a retrospective study with the primary endpoint of assessing the diagnostic effectiveness of cerebrospinal fluid (CSF) tumor markers in LM patients with non‐small‐cell lung cancer (NSCLC). Secondary endpoints included evaluating the concordance with EANO‐ESMO response assessment, determining optimal thresholds, and comparing costs against CSF ctDNA tests.

Results

We retrospectively included 368 patients (151 LM patients, 219 non‐LM patients) as the training set, and another 137 patients (63 LM patients, 74 non‐LM patients) on a consecutive basis as the validation set. The CSF tumor marker panel using a logistic model showed the best performance both in the training set (AUC [95% CI] = 0.992 [0.984–1.000]) and the validation set (AUC [95% CI] = 0.939 [0.891–0.986]). In the response assessment, 167 events were evaluated, with 33 classified as response, 59 as stable, and 75 as progression. We found a concordance with EANO‐ESMO response assessment, and a threshold of ± 25% of the maximal CSF tumor marker level change (maxTML) yielded the optimal predictive performance. Finally, the cost of the CSF tumor marker test (0.76%, IQR (0.30%–1.67%)) was significantly lower in a single hospitalization than CSF ctDNA (62.45%, IQR (32.62%–85.81%)).

Conclusion

Our study demonstrated that the CSF tumor marker test was an accurate, easily interpretable, and cheap tool for both diagnosis and monitoring therapeutic response in LM patients with NSCLC. Trial Registration Chinese Clinical Trial Registry (ChiCTR) number: ChiCTR2300078556

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorMeningeal NeoplasmsMeningeal CarcinomatosisHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdultCirculating Tumor DNAAged, 80 and over

Stichwörter der Autor:innen

CSF tumor marker testdiagnosisleptomeningeal metastasisnon‐small‐cell lung cancerresponse assessment

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Department of Neurosurgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Clinical Pharmacy, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Radiology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ORCID-Profile: Renya Zhan, Qun Chen

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation of China

Zitieren

APA

Huang, K., He, H., Jin, W., Liu, X., Weng, Y., Yan, D., Zhao, Y., Yang, H., Zhan, R., Xu, Q., & Chen, Q. (2025). Tumor Marker Test in Cerebrospinal Fluid for Leptomeningeal Metastasis Diagnosis and Response Assessment in Non‐Small‐Cell Lung Cancer. European Journal of Neurology, 32(6). https://doi.org/10.1111/ene.70245

Vancouver

Huang K, He H, Jin W, Liu X, Weng Y, Yan D, et al. Tumor Marker Test in Cerebrospinal Fluid for Leptomeningeal Metastasis Diagnosis and Response Assessment in Non‐Small‐Cell Lung Cancer. European Journal of Neurology. 2025;32(6). doi:10.1111/ene.70245

BibTeX
@article{Huang2025,
  author = {Huang, Kaiyuan and He, Haifeng and Jin, Weili and Liu, Xueling and Weng, Yuxiang and Yan, Danfang and Zhao, Yilei and Yang, Hanjin and Zhan, Renya and Xu, Qingsheng and Chen, Qun},
  title = {Tumor Marker Test in Cerebrospinal Fluid for Leptomeningeal Metastasis Diagnosis and Response Assessment in Non‐Small‐Cell Lung Cancer},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {6},
  doi = {10.1111/ene.70245}
}
Kostenlos starten →